Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Q&A: Steve Paul

Monday, January 25th, 2010

The interview appears here, as part of our annual January Top 10 Pipelines coverage.

Prasugrel not pleasing

Wednesday, June 3rd, 2009

Since January 2008, FDA has been discussing the benefits over the risks of Eli Lilly’s prasugrel. The drug prevents more heart attacks than Plavix, but causes more internal bleeding, according to a study conducted by Lilly. Consumer health advocates and Dr. Victor Serebruany, who worked on the early development of ...

   
©2010 Canon Communications Pharmaceutical Media Group